A Phase 1 interventional study of nintedanib 25 mg and nintedanib 100 mg in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-17.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this trial is to investigate the relative bioavailability of 100 mg nintedanib given as four capsules of 25 mg nintedanib compared with one capsule of 100 mg nintedanib.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
first test (T), then reference (R) treatment
Drug: nintedanib 25 mg · Drug: nintedanib 100 mg
first reference (R), then test (T) treatment
Drug: nintedanib 25 mg · Drug: nintedanib 100 mg
soft gelatin capsule
soft gelatin capsule
Also known as: Ofev®
Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
Area under the concentration-time curve of the nintedanib in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported.
Time frame: For both arms: Within 3 hours (h) before and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, 34 h, 48 h and 72h after nintedanib administration.
Maximum Measured Concentration of Nintedanib in Plasma (Cmax)
Maximum measured concentration of nintedanib in plasma (Cmax) is reported.
Time frame: For both arms: Within 3 hours (h) before and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, 34 h, 48 h and 72h after nintedanib administration.
Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported.
Time frame: For both arms: Within 3 hours (h) before and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, 34 h, 48 h and 72h after nintedanib administration.
This was a phase I trial to test the relative bioavailability of 100 milligram (mg) nintedanib (Ofev®) given as four capsules of 25 mg compared to one capsule of 100 mg following oral administration in healthy male subjects (an open-label, randomised, single-dose, two-period, two-sequence crossover study).
| Milestone | Nintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T) | Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R) |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
| Milestone | Nintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T) | Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R) |
|---|---|---|
| Started | 10 | 10 |
| Completed | 9 | 9 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Milestone | Nintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T) | Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R) |
|---|---|---|
| Started | 9 | 9 |
| Completed | 9 | 9 |
| Not completed | 0 | 0 |
Area under the concentration-time curve of the nintedanib in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported.
| hours (h) *nanogram(ng)/milliliter (mL) | Nintedanib 1 X 100 mg (R) | Nintedanib 4 X 25 mg (T) |
|---|---|---|
| Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) | 150.65 ± NA | 148.34 ± NA |
Maximum measured concentration of nintedanib in plasma (Cmax) is reported.
| nanogram (ng)/milliliter (mL) | Nintedanib 1 X 100 mg (R) | Nintedanib 4 X 25 mg (T) |
|---|---|---|
| Maximum Measured Concentration of Nintedanib in Plasma (Cmax) | 15.23 ± NA | 15.27 ± NA |
Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported.
| hours * nanogram/milliliter | Nintedanib 1 X 100 mg (R) | Nintedanib 4 X 25 mg (T) |
|---|---|---|
| Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) | 157.55 ± NA | 155.85 ± NA |
Collected over For both arms: From drug administration until 14 days thereafter.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nintedanib 1 X 100 mg (R) | 0/19 (0%) | 0/19 (0%) | 10/19 (52.6%) |
| Nintedanib 4 X 25 mg (T) | 0/19 (0%) | 0/19 (0%) | 5/19 (26.3%) |
| Event | Nintedanib 1 X 100 mg (R) | Nintedanib 4 X 25 mg (T) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/19 | 4/19 |
| Abdominal painGastrointestinal disorders | 2/19 | 0/19 |
| Abdominal pain upperGastrointestinal disorders | 2/19 | 1/19 |
| NauseaGastrointestinal disorders | 2/19 | 1/19 |
| ConstipationGastrointestinal disorders | 0/19 | 1/19 |
| FlatulenceGastrointestinal disorders | 1/19 | 0/19 |
| GastritisGastrointestinal disorders | 1/19 | 0/19 |
| NasopharyngitisInfections and infestations | 1/19 | 0/19 |
| SunburnInjury, poisoning and procedural complications | 1/19 | 0/19 |
| Decreased appetiteMetabolism and nutrition disorders | 1/19 | 0/19 |
Treated set (TS): TS included all subjects who were randomised and treated with at least 1 dose of the investigational medicinal product.
| Age, Continuous(Years) | Nintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T) | Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R) | Total |
|---|---|---|---|
| Mean | 35.2 ± 10.1 | 32.4 ± 7.8 | 33.8 ± 8.9 |
| Sex: Female, Male(Participants) | Nintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T) | Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 10 | 10 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Nintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T) | Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 10 | 10 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Nintedanib 1 X 100 mg (R) / Nintedanib 4 X 25 mg (T) | Nintedanib 4 X 25 mg (T) / Nintedanib 1 X 100 mg (R) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 10 | 10 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Jul 2021 to primary completion in Aug 2021, 1 month.
Results were first posted in Jul 2023, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib